| Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
| 06/15/2023 | Acurx Pharmaceuticals, Inc. | ACXP | Grant | Stock Option | 10k | $2.75 | $27.5k | | 06/15/2023 |
| 01/03/2023 | AFC Gamma, Inc. | | Grant | Common Stock | 963 | $15.57 | $15k | | 01/03/2023 |
| 01/11/2022 | AFC Gamma, Inc. | | Grant | Stock Option (right to buy) | 5k | $20.18 | $100.9k | | 01/11/2022 |
| 07/01/2021 | Acurx Pharmaceuticals, Inc. | ACXP | Grant | Stock Option | 50k | $6.18 | $309k | | 07/01/2021 |
| 03/23/2021 | AFC Gamma, Inc. | | Grant | Stock Option (right to buy) | 700 | $19.00 | $13.3k | | 03/23/2021 |
| 03/23/2021 | AFC Gamma, Inc. | | Purchase | Common Stock | 5k | $19.00 | $95k | | 03/23/2021 |
| 06/06/2018 | Zynerba Pharmaceuticals, Inc. | ZYNE | Grant | Stock Option (right to buy) | 15k | $11.30 | $169.5k | | 06/06/2018 |
| 12/08/2017 | Fifth Street Asset Management Inc. | FSAM | Sale | Class A Common Stock, $0.01 par value per share | 6k | $4.05 | $24.3k | | 12/08/2017 |
| 11/30/2017 | Fifth Street Asset Management Inc. | FSAM | Sale | Class A Common Stock, $0.01 par value per share | 20k | $4.07 | $81.4k | | 11/30/2017 |
| 11/30/2017 | Fifth Street Asset Management Inc. | FSAM | Exercise | Option (right to buy) | 20k | $3.28 | $65.6k | | 11/30/2017 |
| 11/30/2017 | Fifth Street Asset Management Inc. | FSAM | Sale | Class A Common Stock, $0.01 par value per share | 20k | $4.07 | $81.4k | | 11/30/2017 |
| 11/30/2017 | Fifth Street Asset Management Inc. | FSAM | Exercise | Option (right to buy) | 20k | $3.28 | $65.6k | | 11/30/2017 |
| 10/02/2017 | Zynerba Pharmaceuticals, Inc. | ZYNE | Grant | Stock Option (right to buy) | 2.1k | $8.69 | $17.9k | | 10/02/2017 |
| 07/03/2017 | Zynerba Pharmaceuticals, Inc. | ZYNE | Grant | Stock Option (right to buy) | 1.1k | $16.90 | $17.9k | | 07/03/2017 |
| 06/07/2017 | Zynerba Pharmaceuticals, Inc. | ZYNE | Grant | Stock Option (right to buy) | 15k | $18.77 | $281.6k | | 06/07/2017 |
| 05/04/2017 | Fifth Street Asset Management Inc. | FSAM | Grant | Option (right to buy) | 5k | $4.60 | $23k | | 05/04/2017 |
| 04/03/2017 | Zynerba Pharmaceuticals, Inc. | ZYNE | Grant | Stock Option (right to buy) | 880 | $20.32 | $17.9k | | 04/03/2017 |
| 01/17/2017 | PLx Pharma Winddown Corp. | PLXP | Grant | Options | 20k | $1.80 | $36k | | 01/17/2017 |
| 06/16/2016 | Fifth Street Asset Management Inc. | FSAM | Grant | Option (right to buy) | 5k | $4.28 | $21.4k | | 06/16/2016 |
| 05/25/2016 | Zynerba Pharmaceuticals, Inc. | ZYNE | Grant | Stock Option (right to buy) | 15k | $7.90 | $118.5k | | 05/25/2016 |
| 03/14/2016 | Fifth Street Asset Management Inc. | FSAM | Grant | Option (right to buy) | 20k | $3.28 | $65.6k | | 03/14/2016 |
| 01/19/2016 | PLx Pharma Winddown Corp. | PLXP | Grant | Options | 18k | $10.16 | $182.9k | | 01/19/2016 |
| 08/10/2015 | Zynerba Pharmaceuticals, Inc. | ZYNE | Purchase | Common Stock | 12.5k | $14.00 | $175k | | 08/10/2015 |
| 08/04/2015 | Zynerba Pharmaceuticals, Inc. | ZYNE | Grant | Stock Option | 35k | $14.00 | $490k | | 08/04/2015 |
| 06/04/2015 | Fifth Street Asset Management Inc. | FSAM | Grant | Option (right to buy) | 5k | $10.22 | $51.1k | | 06/04/2015 |
| 01/05/2015 | PLx Pharma Winddown Corp. | PLXP | Grant | Options | 15k | $11.35 | $170.2k | | 01/05/2015 |
| 11/04/2014 | Fifth Street Asset Management Inc. | FSAM | Purchase | Class A Common Stock, $0.01 par value per share | 6k | $17.00 | $102k | | 11/04/2014 |
| 10/29/2014 | Fifth Street Asset Management Inc. | FSAM | Grant | Option (right to buy) | 10k | $18.70 | $187k | | 10/29/2014 |
| 03/18/2014 | PLx Pharma Winddown Corp. | PLXP | Purchase | Common Stock, par value $.001 per share | 2k | $12.00 | $24k | | 03/18/2014 |
| 12/03/2013 | RVUE HOLDINGS, INC. | RVUE | Purchase | Common Stock | 1000k | $0.07 | $70k | | 12/03/2013 |
| 12/03/2013 | RVUE HOLDINGS, INC. | RVUE | Grant | Common Stock | 500k | $0.00 | $0 | | 12/03/2013 |
| 08/13/2012 | EPOCRATES INC | EPOC | Grant | Non-Qualified Stock Option (right to buy) | 11.8k | $8.14 | $96k | | 08/13/2012 |